摘要
心房颤动(房颤)是临床上最常见的心律失常之一,约占所有住院心律失常患者的1/3。随着房颤发病率的升高及人口老龄化的加重,房颤的发病人数将会逐年上升。长期的房颤可引起卒中、心力衰竭等一系列不良临床后果,其中卒中是房颤致死致残的最重要原因,而脑卒中则是其最常见的表现形式,故通过抗凝治疗来预防房颤患者出现卒中便成为房颤治疗的核心策略。而在我国目前有相当一部分房颤患者未接受有效的抗凝治疗,这严重影响了房颤患者的预后和正常生活。目前的抗凝药种类繁多,本文就抗凝药物的研究进展进行综述。
Atrial fibrillation(AF)is one of the most common arrhythmias in clinical practice,accounting for about 1/3 of all hospitalized arrhythmic patients.With the increasing morbidity of AF and aggravation of aging of population,the number of AF patients will increase year by year.Long-term AF can cause a series of adverse clinical consequences such as stroke and heart failure,among which apoplexy is the most important cause of death and disability of AF,while stroke is the most common manifestation of it.Therefore,the prevention of stroke in AF patients through anticoagulation therapy has become the core strategy of AF treatment.In China,a considerable number of AF patients have not received effective anticoagulant therapy,which seriously affects the prognosis and normal life of AF patients.At present,there are many kinds of anticoagulant drugs.This article reviews the research progress of anticoagulant drugs.
作者
徐艳莉
田艳丰
梁兆光
XU Yan-li;TIAN Yan-feng;LIANG Zhao-guang(Department of Cardiology,First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150001,China)
出处
《心血管康复医学杂志》
CAS
2024年第3期337-340,共4页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
心房颤动
抗凝药
治疗
Atrial fibrillation
Anticoagulants
Therapy
